Keyword: Ozempic (semaglutide)
Novo Nordisk is firing up its first innovation challenge to scout out tech solutions in diabetes.
Move over, Siri and Alexa: There’s a new voice in town. Meet Sophia, Novo Nordisk’s first chatbot built specifically for people with diabetes.
Pharma's summer TV advertising ended with the same old story for the most part, but a new drug on the top-10 list might shake things up.
The 2018 European Society of Cardiology Congress presented some bombshell data that would shake up the cardiovascular landscape in the coming year.
The approval case for Novo Nordisk’s oral diabetes candidate keeps on building, this time with new data in patients with kidney troubles.
As Novo Nordisk’s highly anticipated semaglutide nears the market, the company has a big decision to make: How will it price the product?
Novo Nordisk expects basal insulin prices to sink even further next year—but that shouldn’t surprise investors too much, the company’s CEO says.
Novo Nordisk debuted its first DTC campaign for Type 2 diabetes drug Ozempic this week, setting the promotional stage for its aspiring blockbuster.
Though Trump convinced Pfizer to delay its planned price increases, Celgene, Roche and Novo have gone through with their own increases in July.
Just eight days after posting a trial win over Merck diabetes stalwart Januvia, Novo Nordisk candidate semaglutide is back with another.
